Safety feature (Falsified Medicines Directive): ‘black’ and ‘white’ lists
We are analysing your feedback
Visit this page again soon to download the outcome to this public feedback.
This consultation ran from
MHRA seeks views on the listing of prescription medicines exempted from the safety feature and non-prescription medicines that must bear the safety feature (MLX387).
PDF, 91.1KB, 5 pages
This file may not be suitable for users of assistive technology. Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email firstname.lastname@example.org. Please tell us what format you need. It will help us if you say what assistive technology you use.
MHRA is consulting on the products that should have the necessary ‘safety features’ in accordance with European law.
Directive 2011/62/EU (the ‘Falsified Medicines Directive’) introduced obligatory ‘safety features’ to verify the authenticity of medicinal products. All prescription medicines will bear the safety features unless they are listed by the European Commission and all non-prescription medicines will not bear the safety features unless they are listed. The MHRA seeks views on products that should be listed.
Published: 1 August 2014